We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Embryonic Neuron-Activating Factor Identified

By Biotechdaily staff writers
Posted on 27 Jan 2004
Researchers have identified a calcium-responsive transactivator called CREST (for calcium-responsive transactivator) as being responsible for activation of neurons during early embryonic development.

CREST, which has been shown to be expressed in the developing brain, is a SYT-related nuclear protein that interacts with adenosine 3',5'-monophosphate (cAMP) response element–binding protein (CREB)–binding protein (CBP).

Investigators at the University of California, San Diego (USA), and Johns Hopkins University (Baltimore, MD, USA) genetically engineered a line of mice lacking the gene for CREST. More...
They reported in the January 9, 2003, issue of Science that these mice were viable but displayed defects in cortical and hippocampal dendrite development. Neurons from these animals grown in tissue culture showed retarded calcium-dependent dendritic growth.

"CREST is the first example of a transcription factor--a protein that turns genes on and off--that appears to be specifically required for the development of brain neurons after birth,” explained senior author Dr. Anirvan Ghosh, professor of biology at the University of California, San Diego. "Humans also have CREST, and the CREST gene sequence is highly similar between mice and humans. If it turns out that CREST plays a role in learning and memory in the mouse, then it is very likely it also plays a similar role in humans.”





Related Links:
University of California, San Diego
Johns Hopkins University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Thyroid Test
Anti-Thyroid EIA Test
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.